Michael Harris Becomes Ethypharm's Chief Operating Officer

Saint-Cloud, France (ots/PRNewswire) -

Ethypharm, a European specialty pharmaceutical company, announces
the appointment of Michael Harris as Chief Operating Officer of the
Ethypharm Group.

(Logo: http://mma.prnewswire.com/media/506947/Ethypharm_Logo.jpg )

Previously Michael was CEO of Martindale Pharma, a leading
UK-based specialty pharmaceutical company providing essential
medicines to over 50 countries around the world and specializing in
the field of opioid addiction, emergency care and sterile injectable
products. Following the acquisition of Martindale by Ethypharm in
February 2017, he has been appointed to COO of the combined group.
In his role, Michael will be responsible for the sales, quality,
manufacturing and industrial teams at Ethypharm.

The acquisition of Martindale Pharma is a key element in
Ethypharm's strategy to build a leading European specialty pharma
company focused upon pain, addiction and critical care.

"I am delighted to become part of the Ethypharm team and am
excited to help our patients that need innovative pain, addiction and
critical care products," said Michael Harris. "Ethypharm is poised
to grow in both its traditional markets and after the acquisition of
Martindale, has the further capability of accelerating growth in the
UK, Middle East and Australia."

Hugues Lecat, CEO of Ethypharm, commented: "I warmly welcome
Michael to Ethypharm. His experience and knowledge in the
pharmaceutical and life sciences industry will lead us to shape
Ethypharm into a European leading specialty pharmaceuticals company
that is providing patients with access to differentiated and
affordable medicines."

With over 20 years in the pharmaceutical and life sciences
industry Michael has held senior managerial positions at major
international life science and healthcare companies. He has
significant experience working across supply chain, manufacturing,
sales, marketing as well as corporate M&A and has worked in both the
UK and Switzerland.

Prior to joining Martindale Pharma, he worked at GE Healthcare as
the General Manager, Commercial for the Research business in EMEA and
USCAN. Before that he spent 10 years at Sigma Aldrich, now part of
Merck KGaA, where he was Managing Director of EMEA and member of the
Corporate Executive team. At Sigma Aldrich, he was directly
responsible for the sales, operations, supply chain and support
functions across the European market.

About Ethypharm

Ethypharm is a specialty European pharmaceutical company with
global reach and a committed player in the treatment of pain and
addiction.

Ethypharm also develops and markets complex generics and essential
medicines that help reduce healthcare costs, particularly in the
field of emergency care and oncology.

The Company employs 1400 people mainly in Europe, and its drugs
are marketed in more than 50 countries.

Our ambition is to become the European leader for the treatment of
pain and addiction, and to help patients around the world gain access
to high quality, essential and affordable medicines.

Press contact - Greta Guzman / presse@ethypharm.com /
+33(0)1-41-12-17-20

ots Originaltext: Ethypharm
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Ethypharm, übermittelt durch news aktuell